You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Main characteristics of study participants

From: Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults

Variable N = 99
Age (years) 15.3 [IQR:13.6-16.7]
Ethnicity  
  Caucasian 83 (85.6)
  African 5 (5.1)
  Hispanic 2 (2.1)
  Roma 2 (2.1)
  Other 5 (5.1)
Female 57(57.6)
CDC clinical stage  
  A 25 (25.5)
  B 29 (29.6)
  C 44 (44.9)
CDC immunological stage  
  1 2 (2.1)
  2 31 (31.3)
  3 66 (66.6)
Tanner stage  
  1 4(4.1)
  2 8 (8.1)
  3 14 (14.1)
  4 18 (18.1)
  5 55(55.6)
Weight (kg) 51.1 [44.7-59.2]
  Weight Z score −0.2 [−0.79-0.76]
Height (cm) 160 [153.5-166.9]
  Height Z score −0.03 [−1-0.7]
BMI 19.9 [18.3-22.3]
  Age at menarche (years) 12.0 [11.7-13.0]
Treatment  
  HAART 92 (92.9)
  No treatment 7 (7.1)
Total ARV exposure (years) 11.4 [9.1-12.8]
HAART exposure (years) 9.4 [6.7-10.7]
PI exposure (months) 90.4 [44.1-127.8]
NNRTI exposure (months) 39.8[3.3-85.7]
Type of treatment  
  2 NRTIs + 1 PI 35 (38.1)
  2 NRTIs + 1 NNRTI 28 (30.4)
  2 NRTIs + 1 PI +1 NNRTI 21 (22.8)
  Other 8 (8.7)
Viral load (copies/ml) 50 [50–200]
Viral load (<50 copies/ml) 66 (66.7)
CD4 count (cs/mm 3 ) 737.0 [503.8-975.5]
CD4 % 33 [25.4-38.5]
CD4 nadir (cs/mm 3 ) 252 [102–442]
  1. Continuous variables were expressed as median and interquartile range (IQR) and categorical variables were expressed as counts (N) and percentages (%).
  2. Abbreviations: IQR interquartile range, CDC centers for disease control and prevention, HAART highly active antiretroviral therapy, ARV antiretroviral, BMI body mass index, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside analog, PI protease inhibitor.